Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Shire Announces Second Quarter Earnings and Increases Full Year Non GAAP Diluted EPS Guidance to Mid-to-High Single Digit Growth


News provided by

Shire plc

23 Jul, 2015, 11:01 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Ireland, July 23, 2015 /PRNewswire/ --

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to June 30, 2015.

   
                                                                                 Non GAAP
    Financial Highlights                                   Q2 2015    Growth(1) CER(1)(2)
                                                               $1,476
    Product sales                                             million +0%       +6%
                                                               $1,467
    Product sales excluding INTUNIV(R)                        million +7%       +12%
                                                               $1,558
    Total revenues                                            million +4%       +9%

    Non GAAP operating income                            $614 million -3%       +0%
    US GAAP operating income from continuing operations  $133 million -61%(3)

    Non GAAP EBITDA margin (excluding royalties & other
    revenues)(4)                                                  39% -5pps(5)
    US GAAP net income margin(6)                                  10% -25pps(3)

    Non GAAP diluted earnings per ADS                           $2.63 -2%       +3%
    US GAAP diluted earnings per ADS                            $0.81 -70%

    Non GAAP cash generation                             $505 million -23%
    Non GAAP free cash flow                              $432 million -48%
    US GAAP net cash provided by operating activities    $452 million -46%

(1) Percentages compare to equivalent 2014 period.

(2) On a Constant Exchange Rate ("CER") basis, which is a Non GAAP measure.

(3) Q2 2015 includes a net charge of $243 million related to impairment of SHP625 & SHP608. Impairment charges of $523 million are partially offset by the associated credits of $280 million relating to a change in the fair value of contingent consideration liabilities.

(4) Non GAAP earnings before interest, tax, depreciation and amortization ("EBITDA") as a percentage of product sales, excluding royalties and other revenues.

(5) Percentage point change ("PPS").

(6) US GAAP net income as a percentage of total revenues.

The Non GAAP financial measures included within this release are explained on pages 29 - 30, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 21 - 26.

Highlights: 

  • Q2 product sales growth of 7% excluding INTUNIV (12% on a Non GAAP CER basis); first half product sales excluding INTUNIV up 11% (16% on a Non GAAP CER basis)
  • Product sales this quarter driven by strong performance from  VYVANSE®, FIRAZYR®, LIALDA®/MEZAVANT®
  • Early positive momentum from NPS Pharmaceuticals ("NPS") products, NATPARA® and GATTEX®/REVESTIVE®; NPS commercial integration complete
  • Significant Q2 investment in future growth drivers including the launch of the Binge Eating Disorder ("BED") adult indication, market expansion of VYVANSE in adults and behind GATTEX/REVESTIVE and NATPARA acquired with NPS
  • Innovative pipeline advancing, with SHP465 pediatric Phase 3 initiated ahead of schedule, favorable FDA feedback on path forward for Maribavir Phase 3, and OPUS 3 for lifitegrast fully enrolled
  • SHP625 Phase 2 studies in two rare cholestatic liver indications (PBC, PFIC) did not meet primary endpoints; totality of data under review to determine path forward
  • Non-cash impairments for SHP625 and SHP608 affect US GAAP operating income; payments related to purchase of NPS impact cash generation(1)
  • Non GAAP diluted earnings per ADS growth guidance increased to mid-to-high single digit percent range for the full year (2015)

-------------------------------------------------- 

1.) Q2 2015 includes a net charge of $243 million related to impairment of SHP625 & SHP608. Impairment charges of $523 million are partially offset by the associated credits of $280 million relating to a change in the fair value of contingent consideration liabilities. 

Flemming Ornskov, M.D. Chief Executive Officer, commented: 

Alongside our strong performance in the first half of 2015, we are progressing our transformation to becoming a leading global biotech company and are confident in delivering on our 10x20 ambitions. During the second quarter, we delivered 7% product sales growth on a reported basis and 12% on a Non GAAP CER basis, in both cases excluding INTUNIV. This is a solid performance, achieved amid continued investment in future innovation and growth drivers. I am especially pleased with the performance of VYVANSE both in the adult ADHD market and with the launch of the new adult indication for moderate to severe Binge Eating Disorder. The early performance of the products we gained from NPS underscores our ability to acquire and integrate assets and deliver value. Given our first half performance and confidence in the underlying business, we are increasing our full-year earnings guidance, and now expect Non GAAP diluted earnings per ADS growth to be in the mid-to-high single digit percent range for 2015. Additionally, we expect to meet our 10x20 target of $6.5 billion of product sales in 2016, and exceed it with the contribution from our recent acquisition of NPS.

FINANCIAL SUMMARY 

Second Quarter 2015 Unaudited Results 

   
                               Q2 2015                               Q2 2014
                 US GAAP    Adjustments    Non GAAP    US GAAP    Adjustments  Non GAAP
                      $M             $M          $M         $M             $M          $M
    Total
    revenues       1,558              -       1,558      1,502              -       1,502
    Operating
    income           133            481         614        338            292         630

    Diluted
    earnings
    per ADS        $0.81          $1.82       $2.63      $2.66          $0.01       $2.67

  • Product sales excluding INTUNIV were up 7% (up 12% on a Non GAAP CER basis), with strong growth from VYVANSE(1) (up 18% to $425 million), LIALDA/MEZAVANT (up 10% to $158 million), and FIRAZYR (up 17% to $104 million).  GATTEX/REVESTIVE continued to gain positive momentum with $37 million of sales and NATPARA had strong initial sales of $6 million.
  • Total product sales including INTUNIV were broadly flat on Q2 2014 (up 6% on a Non GAAP CER basis) at $1,476 million (Q2 2014: $1,470 million) as product sales in Q2 2015 were held back by significantly lower INTUNIV sales (down
    91% to $9 million) following the introduction of generic competition from December 2014.

    As expected, product sales growth in Q2 2015 was also held back by over 5 percentage points due to foreign exchange headwinds from the strong US dollar, primarily affecting sales of ELAPRASE®, REPLAGAL® and VPRIV®.
  • Total revenues were up 4% to $1,558 million (Q2 2014: $1,502 million), as Q2 2015 benefited from higher royalties, principally the first time inclusion of a full quarter of SENSIPAR® royalties acquired with NPS.
  • On a Non GAAP basis:

    Operating income was down 3% to $614 million (Q2 2014: $630 million) as combined R&D and SG&A costs increased at a higher rate (up 16%) than total revenues (up 4%).  Compared to Q2 2014, R&D costs increased by 14% and SG&A costs increased by 17%, in part due to the inclusion of a first full quarter of NPS operating costs.

    Non GAAP EBITDA margin (excluding royalties and other revenues) was 39%, down 5 percentage points compared to Q2 2014 (Q2 2014: 44%), as we invested behind the launch of VYVANSE for the treatment of moderate to severe BED in adults, continued the progression of our pipeline and invested behind GATTEX and NATPARA acquired with NPS.

    On a US GAAP basis (from continuing operations):

    Operating income was down 61% to $133 million (Q2 2014: $338 million).  US GAAP operating income in Q2 2015 was impacted by IPR&D impairment charges ($523 million) relating to SHP625(2) and SHP608(3), offset by the partial release of associated contingent consideration liabilities ($280 million).
  • Non GAAP diluted earnings per American Depository Share ("ADS") decreased 2% to $2.63 (Q2 2014: $2.67) primarily due to the lower Non GAAP operating income partially offset by a lower effective tax rate on Non GAAP income.

    On a US GAAP basis diluted earnings per ADS decreased 70% to $0.81 (Q2 2014: $2.66) primarily due to lower US GAAP operating income.
  • Cash generation, a Non GAAP measure, was 23% lower at $505 million (Q2 2014: $659 million).  Underlying strong cash generation was held back by payments relating to the acquisition and integration of NPS and the timing of rebate payments in Q2 2015.

    Free cash flow, a Non GAAP measure, was down 48% to $432 million (Q2 2014: $830 million), due to lower cash generation and when compared to Q2 2014 which includes the benefit of a $248 million repayment received from the Canadian revenue authorities.

    On a US GAAP basis, net cash provided by operating activities was down 46% to $452 million (Q2 2014: $834 million), as Q2 2014 benefited from the $248 million repayment received from the Canadian revenue authorities.
  • Net debt, a Non GAAP measure, at June 30, 2015 was $2,253 million (December 31, 2014: Net cash of $2,119 million) reflecting the use of cash and cash equivalents and borrowings incurred to fund the acquisition of NPS.

    On a US GAAP basis, cash and cash equivalents were $64 million at June 30, 2015 (December 31, 2014: $2,982 million).

--------------------------------------------------

1.) Lisadexamfetamine dimesylate ("LDX") currently marketed as VYVANSE in the US & Canada, VENVANSE® in Latin America and ELVANSE® in certain territories in the EU for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD") and in the US for the treatment of moderate to severe Binge Eating Disorder in adults.

2.) For the treatment of Cholestatic Liver Disease.

3.) For the treatment of Dystrophic Epidermolysis Bullosa.

OUTLOOK 

Following our strong performance in the first half of 2015, we've increased our guidance for Non GAAP diluted earnings per ADS to mid-to-high single digits growth in 2015 (prior guidance: mid-single digits).

On a Non GAAP CER basis we now expect product sales growth in the high single digits (prior guidance: mid-to-high single digits). When excluding INTUNIV, we anticipate low teens product sales growth on a Non GAAP CER basis (prior guidance: low double digit).

We now anticipate product sales growth to increase 4-5% on a reported basis (prior guidance: low-to-mid single digits). We continue to expect product sales growth to be held back three to four percentage points by foreign exchange headwinds which continue to most significantly impact ELAPRASE, REPLAGAL and VPRIV sales.

Royalties and other revenues are now expected to increase by 45-55% in 2015 (prior guidance: 30-40% higher).

Our Non GAAP gross margin is expected to be in line with 2014 (2014: 85.8%).

We continue to expect combined Non GAAP R&D and SG&A to increase in the high single digits.  We expect that operating cost growth will moderate in the second half of the year as we compare against higher 2014 comparatives.

We expect our Non GAAP net interest and other expense to be in line with 2014 levels.

For 2015, we expect our effective tax rate on Non GAAP income to be in the range of 15-17%, before reverting to the 17-19% range in 2016 and beyond.

Taken together, we've increased our earnings guidance for the full year 2015, and now expect to deliver Non GAAP diluted earnings per ADS growth in the mid-to-high single digits in 2015 (low double digit growth on a Non GAAP CER basis).

Additionally, we expect to meet our 10x20 target of $6.5 billion of product sales in 2016, and exceed it with the contribution from our recent acquisition of NPS.

SECOND QUARTER 2015 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS 

Products 

INTUNIV - for the treatment of ADHD in the European Union

  • The Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") is expected to issue an opinion at its July meeting on whether to recommend a marketing authorization approval for the INTUNIV (guanfacine) extended release drug product, a non-stimulant proposed to treat ADHD in paediatric patients.  The July CHMP meeting is held July 20-23, 2015.

RESOLOR - for the Symptomatic Treatment of Chronic Constipation in Men

  • On May 27, 2015 Shire received the EC decision amending the terms of the Resolor Marketing Authorisation to the use of RESOLOR in adults for the symptomatic treatment of chronic constipation for whom laxatives fail to provide adequate relief. In Europe, RESOLOR was initially approved for use in women only, so the new variation extends the use of this treatment to male patients.

VYVANSE - for the treatment of moderate to severe BED in adults

  • Topline results from a 39-week, long-term maintenance of efficacy study (SPD489-346) in adults with moderate to severe BED showed VYVANSE superior to placebo (p<.001) on the primary efficacy endpoint of time to relapse of binge eating symptoms. At the conclusion of the trial, patients continuing on VYVANSE had a lower proportion of relapse of 5/136 (3.7%) as compared to patients continuing on placebo 42/131 (32.1%).
  • The results of a separate, 12-month open-label safety extension study (SPD489-345) were generally consistent with the safety profile currently outlined in the United States Prescribing information.
  • Based on the results of these studies, the Company plans to submit a supplemental New Drug Application by year end to the US Food and Drug Administration ("FDA"). The FDA will evaluate adding this data to the current labeling for VYVANSE.

Pipeline 

We continued to advance our broad and deep pipeline over the course of the second quarter.

SHP606 (lifitegrast) - for the treatment of Dry Eye Disease

  • Shire has fully enrolled a Phase 3 safety and efficacy study (OPUS-3) in support of potential US and potential international regulatory submissions. OPUS-3 is a multicenter, randomized, double-masked, placebo-controlled, parallel arm study with a 14 day open-label placebo screening run-in period followed by a 12 week randomized, masked treatment period with a primary efficacy endpoint in subjective patient reported symptoms of dry eye disease as measured by the eye dryness score.

SHP465 - for the treatment of adults with ADHD

  • On April 7, 2015 Shire announced that it had reached an agreement with the FDA on a clear regulatory path for SHP465.  Shire has begun dosing patients in a Phase 3 study designed to evaluate the efficacy of SHP465 administered as a daily morning dose compared to a placebo in the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.

SHP620 (maribavir) - for the treatment of cytomegalovirus infection in transplant patients

  • In late June 2015, Shire conducted an end of Phase 2 meeting with the FDA and received further clarity on the path forward.  Based on this feedback, Shire is considering progressing the program into Phase 3 in 2016.

SHP631 - for the treatment of both the central nervous system ("CNS") and somatic manifestations in patients with Hunter syndrome ("MPS II")

  • In Q2 2015, a Phase 1 trial of SHP631 (also known as AGT-182) was initiated. SHP631 is an investigational enzyme replacement therapy for the potential treatment of both the CNS and somatic manifestations in patients with MPS II.

SHP625 - for the treatment of cholestatic liver disease

  • In late May 2015, Shire received results from the CLARITY trial, a 13 week, double-blind, placebo-controlled Phase 2 study in combination with Ursodeoxycholic Acid in Primary Biliary Cirrhosis. SHP625 did not meet the primary endpoint as measured by change in pruritus or the secondary endpoint in level of liver disease as measured by alkaline phosphatase. However, there was a significant reduction in mean serum bile acid levels versus placebo.
  • In June 2015, Shire also received preliminary results from an interim analysis of the INDIGO study, a 72 week open label Phase 2 study in Progressive Familial Intraheptic Cholestatis. The interim analysis was based on the first 12 subjects who completed 13 weeks of treatment per protocol. SHP625 was well tolerated but there was no statistically significant reduction in mean serum bile levels from baseline. A change from baseline analysis was planned as there is no placebo treatment arm in this study. The changes from baseline for pruritus did reach statistical significance. 5 of the 20 patients who received the drug experienced sustained decreases from baseline in serum bile acids ranging from 86 to 99% and also experienced marked reductions in pruritus as evidenced by absence of or only mild scratching at their last evaluation in this ongoing study.  In this subset of patients where biomarkers of liver damage were elevated at baseline, as assessed by alanine transaminase and Total Bilirubin, these values were normalized during the study.  Shire continues to analyze the totality of the data to determine an appropriate path forward.

BOARD AND COMMITTEE CHANGES 

On June 11, 2015 Shire announced the appointment of Olivier Bohuon to the Shire Board of Directors as a Non-Executive Director. Olivier will also be a member of the Science & Technology Committee of the Shire Board. Both appointments were effective from July 1, 2015.

DIVIDEND 

In respect of the six months ended June 30, 2015 the Board resolved to pay an interim dividend of 4.21 US cents per Ordinary Share (2014: 3.83 US cents per Ordinary Share).

Dividend payments will be made in Pounds Sterling to holders of Ordinary Shares and in US Dollars to holders of ADSs. A dividend of 2.69(1) pence per Ordinary Share (an increase of 20% compared to 2014: 2.24 pence) and 12.63 US cents per ADS (an increase of 10% compared to 2014: 11.49 US cents) will be paid on October 2, 2015 to shareholders on the register as at the close of business on September 4, 2015.

(1) Translated using a GBP:USD exchange rate of 1.5631

ADDITIONAL INFORMATION 

The following additional information is included in this press release:

   
                                                               Page
    Overview of Second Quarter 2015 Financial Results            8
                                Financial Information           12
                              Non GAAP Reconciliation           21
                                     Notes to Editors           27
                           Forward-Looking Statements           28
                                    Non GAAP Measures           29
                                          Trade Marks           30

Dial in details for thelive conference call for investors at 14:00 BST / 09:00 EDT on July 23, 2015: 

   
    UK dial in:                   0808 237 0030 or 020 3139 4830
    US dial in:                   1 866 928 7517 or 1 718 873 9077
    International Access Numbers: Click here
    Password/Conf ID:             25841912#
    Live Webcast:                 Click here

The quarterly earnings presentation will be available today at 13:00 BST / 08:00 EDT on:

- Shire.com Investors section

- Shire's IR Briefcase in the iTunes Store

OVERVIEW OF SECOND QUARTER 2015 FINANCIAL RESULTS 

1.     Product sales  

For the three months to June 30, 2015 product sales were broadly flat on Q2 2014 at $1,476 million (Q2 2014: $1,470 million) and represented 95% of total revenues (Q2 2014: 98%).

   
                                                                           US Exit Market
                                           Year on year growth                Share(2)
                                                   Non
                         Sales                    GAAP
    Product sales         $M      Sales          CER(1)      US Rx(2)

    VYVANSE              424.8      +18%            +20%         +8%              16%
    LIALDA/MEZAVANT      157.9      +10%            +12%         +9%              35%
    ELAPRASE             146.5       -4%             +9%         n/a(3)           n/a(3)
    CINRYZE              138.8       +7%             +8%         n/a(3)           n/a(3)
    REPLAGAL             116.9      -10%             +4%         n/a(4)           n/a(4)
    FIRAZYR              104.1      +17%            +20%         n/a(3)           n/a(3)
    ADDERALL XR(R)        86.0      -14%            -13%         +12%             5%
    VPRIV                 84.7       -6%             +3%         n/a(3)           n/a(3)
    PENTASA(R)            66.3       +5%             +5%         -7%              12%
    GATTEX/REVESTIVE(R)   37.3       n/a             n/a         n/a(3)           n/a(3)
    INTUNIV                9.5      -91%            -90%         -65%             1%
    NATPARA                5.9       n/a             n/a         n/a(3)           n/a(3)
    OTHER                 97.5      -13%             -2%         n/a              n/a
                        
    Total              1,476.2        0%             +6%

  1. On a Constant Exchange Rate ("CER") basis, which is a Non GAAP measure.
  2. Data provided by IMS Health National Prescription Audit ("IMS NPA"). Exit market share represents the average US market share in the month ended June 30, 2015.
  3. IMS NPA Data not available.
  4. Not sold in the US in Q2 2015.

VYVANSE - ADHD and BED 

VYVANSE product sales grew strongly (up 18%) in Q2 2015 compared to Q2 2014, primarily due to higher prescription demand in both the US and ROW markets and the benefit of a price increase taken since Q2 2014.  Sales also benefited from higher stocking in Q2 2015 compared to Q2 2014.  VYVANSE was made available in mid-February for moderate to severe BED in adults and we have been pleased with the overall increase in VYVANSE prescriptions since the product became available for that indication.

LIALDA/MEZAVANT - Ulcerative Colitis 

Product sales for LIALDA/MEZAVANT in Q2 2015 were up 10%, primarily driven by higher prescription demand due to higher market share and the benefit of a price increase taken since Q2 2014. Growth was partially offset by higher sales deductions as a percentage of product sales.

ELAPRASE - Hunter syndrome 

ELAPRASE product sales in Q2 2015 were down 4% compared to Q2 2014, reflecting the negative impact of foreign exchange movements partially offset by higher unit sales from an increase in the number of patients on therapy.  On a Non GAAP CER basis ELAPRASE sales were up 9% compared to Q2 2014.

CINRYZE - for the prophylactic treatment of Hereditary Angioedema ("HAE") 

CINRYZE sales were up 7% on Q2 2014 (up 8% on a Non GAAP CER basis), primarily driven by strong growth in patients on therapy and the benefit of a price increase taken since Q2 2014, partially offset by destocking in the quarter.

REPLAGAL - Fabry disease 

REPLAGAL sales were down 10% compared to Q2 2014, driven primarily by the negative impact of foreign exchange.  On a Non GAAP CER basis REPLAGAL sales were up 4% compared to Q2 2014.

FIRAZYR - for the treatment of acute HAE attacks 

FIRAZYR product sales were up 17% (up 20% on a Non GAAP CER basis), primarily due to growth in patients on therapy and a price increase taken in January 2015.

ADDERALL XR - ADHD 

ADDERALL XR product sales were down 14% in Q2 2015, increased prescription demand (up 12%) was more than offset by the effect of higher sales deductions as a percentage of product sales in Q2 2015 compared to Q2 2014.

VPRIV - Gaucher disease 

VPRIV product sales in Q2 2015 were down 6% (up 3% on a Non GAAP CER basis).  Continued growth in the number of patients on therapy was more than offset by the negative impact of foreign exchange movements.  

PENTASA - Ulcerative Colitis 

PENTASA product sales increased in Q2 2015 (up 5%) driven by price increases taken since Q2 2014, partially offset by higher sales deductions as a percentage of product sales and a decrease in prescription demand.

GATTEX/REVESTIVE - Short Bowel Syndrome ("SBS") 

Shire acquired GATTEX/REVESTIVE through its acquisition of NPS on February 21, 2015, and recorded sales of $37 million in Q2 2015 (up 70% on a pro-forma basis(1)).

(1) Sales prior to February 21, 2015 were recorded by NPS, prior to the acquisition by Shire.

INTUNIV - ADHD 

INTUNIV product sales were down 91% in Q2 2015 reflecting the impact of generic competitors in December 2014 and June 2015, which resulted in lower prescription demand and significantly higher sales deductions as a percentage of product sales.

NATPARA - Hypoparathyroidism 

Shire made NATPARA available on April 1, 2015, after acquiring the product through its acquisition of NPS.  In Q2 2015 sales of $6 million were recorded.

2.     Royalties 

   
                                                           Year on year growth
                                   Royalties
                                    to Shire
    Product                            $M        Royalties                        CER

    SENSIPAR(R)                       34.8          n/a                           n/a
    FOSRENOL(R)              1.00     10.8         +15%                          +36%
    3TC(R) and ZEFFIX(R)     1.00     10.5         +27%                          +27%
    ADDERALL XR              1.00     6.6          +45%                          +45%
    INTUNIV                           6.1           n/a                           n/a
    Other                    1.00     10.3         +47%                          +50%
    Total                    1.00     79.1        +171%                         +178%

Royalty income increased by 171% in Q2 2015 due to the inclusion of royalty income receivable from Amgen for SENSIPAR (following the acquisition of NPS by Shire), and the royalties receivable from Actavis on its generic sales of INTUNIV.

3.     Financial details 

Cost of product sales  

   
                                                 % of                    % of
                                              product                 product
                                Q2 2015         sales   Q2 2014         sales
                                     $M                      $M
      Cost of product sales (US
                          GAAP)   228.0           15%     277.0           19%
    Unwind of inventory fair
    value step-up                 (5.1)                  (33.7)
    Costs of employee retention
    awards following AbbVie's
    terminated offer for Shire    (2.8)                       -
    Depreciation                 (13.1)                  (17.8)
    Cost of product sales (Non
    GAAP)                         207.0           14%     225.5           15%

Non GAAP cost of product sales as a percentage of product sales decreased by 1 percentage point in Q2 2015 compared to the same period in 2014, reflecting lower inventory write-offs in Q2 2015.

US GAAP cost of product sales as a percentage of product sales decreased by 4 percentage points in Q2 2015 due to lower charges in relation to the unwind of the fair value adjustment on acquired inventories.

R&D  

   
                                                 % of                    % of
                                              product                 product
                                Q2 2015         sales   Q2 2014         sales
                                     $M                      $M
    R&D (US GAAP)                 775.9           53%     236.9           16%
    Impairment of IPR&D
    intangible assets           (523.3)                  (22.0)
    Costs of employee retention
    awards following AbbVie's
    terminated offer for Shire    (5.7)                       -
    Depreciation                  (8.9)                   (5.8)
    R&D (Non GAAP)                238.0           16%     209.1           14%

Non GAAP R&D increased by $28.9 million, or 14% in Q2 2015, due to the inclusion of a first full quarter of NPS R&D and continued investment in existing pipeline programs.

US GAAP R&D increased by $539.0 million, or 228% as Q2 2015 included intangible asset impairment charges related to the SHP625 IPR&D asset ($347 million), due to lower probability of regulatory approval following trial results, and impairment charges related to the SHP608 IPR&D asset ($177 million), due to pre-clinical toxicity findings.

SG&A 

   
                                                 % of                    % of
                                              product                 product
                                Q2 2015         sales   Q2 2014         sales
                                     $M                      $M
    SG&A (US GAAP)                627.3           42%     496.2           34%
    Intangible asset
    amortization                (131.3)                  (61.2)
    Legal and litigation costs    (1.9)                   (2.2)
    Costs incurred in
    connection with AbbVie's
    terminated offer for Shire
    (including employee
    retention awards)            (17.5)                  (19.1)
    Depreciation                 (17.9)                  (21.1)
    SG&A (Non GAAP)               458.7           31%     392.6           27%

Non GAAP SG&A increased by $66.1 million, or 17%, due to increased investment behind launches, including the successful launch of VYVANSE for the treatment of moderate to severe BED in adults, and the first time inclusion of a full quarter of NPS's SG&A costs.

US GAAP SG&A increased by $131.1 million, or 26%, in part as a result of higher amortization charges on intangible assets acquired with NPS.

Gain on sale of product rights 

For the three months to June 30, 2015 Shire recorded a net gain on sale of non-core product rights of $7.1 million (Q2 2014: $3.8 million) due primarily to the re-measurement of the contingent consideration receivable relating to the divestment of DAYTRANA.

Reorganization costs 

For the three months to June 30, 2015 Shire recorded reorganization costs of $13.3 million (Q2 2014:  $45.8 million). Costs in the second quarter of 2015 primarily related to the relocation of roles from Chesterbrook to Lexington.

Integration and acquisition costs 

For the three months to June 30, 2015 Shire recorded a net credit for integration and acquisition costs of $212.4 million, which comprised integration and acquisition costs primarily related to NPS of $45.7 million and a net credit of $258.1 million for the change in fair value of contingent consideration liabilities, primarily relating to SHP625 (acquired with Lumena Pharmaceuticals, Inc.) and SHP608 (acquired with Lotus Tissue Repair Inc).

In Q2 2014 Shire recorded integration and acquisition costs of $112.1 million. This net charge included costs of $31.5 million related to the acquisition and integration of ViroPharma and $80.6 million relating to the change in fair values of contingent consideration liabilities.

Interest expense 

For the three months to June 30, 2015 Shire incurred interest expense of $11.3 million (Q2 2014: $11.1 million). Interest expense in Q2 2015 primarily related to interest and the amortization of financing fees incurred on borrowings to fund the NPS acquisition. Interest expense in Q2 2014 principally related to interest and amortization of issue costs incurred on borrowings to fund the ViroPharma acquisition.

Taxation 

The effective rate of tax on Non GAAP income in Q2 2015 was 13% (Q2 2014: 16%), and on a US GAAP basis the effective rate of tax was -37% (Q2 2014: -51%).

The effective rate of tax in Q2 2015 on Non GAAP income from continuing operations is lower than the same period in 2014 primarily due to the re-measurement of uncertain tax positions relating to ongoing tax audits and the release of certain valuation allowances in the quarter.

The effective rate of tax in Q2 2015 on US GAAP income from continuing operations is negative primarily due to the reduction in deferred tax liabilities in relation to the impairment of IPR&D intangible assets, the re-measurement of uncertain tax positions relating to ongoing tax audits and the release of certain valuation allowances all recognised during the quarter.

The effective rate of tax in Q2 2014 on US GAAP income was negative primarily due to the recognition of a net tax credit in relation to the settlement of tax positions with the Canadian revenue authorities.

Discontinued operations 

The loss from discontinued operations for the three months to June 30, 2015 was $4.5 million net of tax (Q2 2014: $5.2 million) relating to costs associated with the divestment of the DERMAGRAFT business.

FINANCIAL INFORMATION 

TABLE OF CONTENTS 

   
                                                             Page

    Unaudited US GAAP Consolidated Balance Sheets              13

    Unaudited US GAAP Consolidated Statements of Income        14

    Unaudited US GAAP Consolidated Statements of Cash
    Flows                                                      16

    Selected Notes to the Unaudited US GAAP Financial
    Statements
      (1) Earnings per share                                   18
      (2) Analysis of revenues                                 19

    Non GAAP reconciliation                                    21

Unaudited US GAAP financial position as of June 30, 2015

Consolidated Balance Sheets 

   
                                                         June 30,    December 31,
                                                            2015            2014
                                                              $M              $M
    ASSETS
    Current assets:
    Cash and cash equivalents                               64.0         2,982.4
    Restricted cash                                         74.0            54.6
    Accounts receivable, net                             1,099.2         1,035.1
    Inventories                                            632.8           544.8
    Deferred tax asset                                     455.4           344.7
    Prepaid expenses and other current assets              221.6           221.5

    Total current assets                                 2,547.0         5,183.1

    Non-current assets:
    Investments                                             50.0            43.7
    Property, plant and equipment ("PP&E"), net            816.7           837.5
    Goodwill                                             4,173.2         2,474.9
    Other intangible assets, net                         9,310.4         4,934.4
    Deferred tax asset                                     107.9           112.1
    Other non-current assets                                25.3            46.4

    Total assets                                        17,030.5        13,632.1

    LIABILITIES AND EQUITY
    Current liabilities:
    Accounts payable and accrued expenses                1,939.7         1,909.4
    Short term borrowings                                2,229.9           850.0
    Other current liabilities                              145.5           262.5

    Total current liabilities                            4,315.1         3,021.9

    Non-current liabilities:
    Long term borrowings                                    73.9               -
    Deferred tax liability                               2,808.4         1,210.6
    Other non-current liabilities                          718.7           736.7

    Total liabilities                                    7,916.1         4,969.2

    Equity:
    Common stock of 5p par value; 1,000 million
    shares authorized; and 600.5 million shares
    issued and outstanding (2014: 1,000 million
    shares authorized; and 599.1 million shares
    issued and outstanding)                                 58.9            58.7
    Additional paid-in capital                           4,409.3         4,338.0
    Treasury stock: 9.8 million shares (2014: 10.6
    million)                                             (323.5)         (345.9)
    Accumulated other comprehensive loss                 (111.5)          (31.5)
    Retained earnings                                    5,081.2         4,643.6

    Total equity                                         9,114.4         8,662.9

    Total liabilities and equity                        17,030.5        13,632.1

Unaudited US GAAP results for the three months and six months to June 30, 2015

Consolidated Statements of Income 

   
                                     3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
                                     $M                 $M           $M                 $M
    Revenues:
    Product sales               1,476.2            1,469.6      2,899.4            2,777.7
    Royalties                      79.1               29.2        141.9               61.5
    Other revenues                  2.3                3.3          4.7                9.7
    Total revenues              1,557.6            1,502.1      3,046.0            2,848.9

    Costs and expenses:
    Cost of product sales         228.0              277.0        455.8              506.5
    R&D(1)                        775.9              236.9        969.6              597.4
    SG&A(2)                       627.3              496.2      1,133.9              926.5
    Gain on sale of product
    rights                        (7.1)              (3.8)       (12.3)             (40.2)
    Reorganization costs           13.3               45.8         28.5               95.2
    Integration and
    acquisition costs           (212.4)              112.1      (136.7)              118.7
    Total operating expenses    1,425.0            1,164.2      2,438.8            2,204.1

    Operating income from
    continuing operations         132.6              337.9        607.2              644.8

    Interest income                 0.6               18.7          2.6               19.2
    Interest expense             (11.3)             (11.1)       (20.9)             (18.9)
    Other (expense)/income,
    net                           (2.0)                3.3          2.3                8.0
    Total other
    (expense)/income, net        (12.7)               10.9       (16.0)                8.3

    Income from continuing
    operations before income
    taxes and equity in
    earnings/(losses) of
    equity method investees       119.9              348.8        591.2              653.1
    Income taxes                   44.1              176.5       (13.3)              125.9
    Equity in
    earnings/(losses) of
    equity method investees,
    net of taxes                    0.1                3.0        (0.9)                2.4
    Income from continuing
    operations, net of tax        164.1              528.3        577.0              781.4
    Loss from discontinued
    operations, net of taxes      (4.5)              (5.2)        (7.0)             (27.9)
    Net income                    159.6              523.1        570.0              753.5

  1. R&D costs include impairments of IPR&D intangible assets of $523.3 million for the three months to June 30, 2015 (2014: $22.0 million) and $523.3 million for the six months to June 30, 2015 (2014: $188.0 million).
  2. SG&A costs include amortization of intangible assets relating to intellectual property rights acquired of $131.3 million for the three months to June 30, 2015 (2014: $61.2 million) and $219.6 million for the six months to June 30, 2015 (2014: $119.0 million).

Unaudited US GAAP results for the three months and six months to June 30, 2015

Consolidated Statements of Income (continued) 

   
                                     3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
    Earnings per Ordinary
    Share - basic
    Earnings from continuing
    operations                    27.8c              90.1c        97.8c             133.6c
    Loss from discontinued
    operations                   (0.8c)             (0.9c)       (1.2c)             (4.8c)

    Earnings per Ordinary
    Share - basic                 27.0c              89.2c        96.6c             128.8c

    Earnings per ADS - basic      81.0c             267.6c       289.8c             386.4c

    Earnings per Ordinary
    Share - diluted
    Earnings from continuing
    operations                    27.7c              89.5c        97.3c             132.3c
    Loss from discontinued
    operations                   (0.8c)             (0.9c)       (1.2c)             (4.7c)

    Earnings per Ordinary
    Share - diluted               26.9c              88.6c        96.1c             127.6c

    Earnings per ADS -
    diluted                       80.7c             265.8c       288.3c             382.8c

    Weighted average number
    of shares:
                               Millions           Millions     Millions           Millions

    Basic                         590.5              586.4        589.8              585.3
    Diluted                       593.2              590.3        593.0              590.3

Unaudited US GAAP results for the three months and six months to June 30, 2015

Consolidated Statements of Cash Flows 

   
                                                3 months to June 30,   6 months to June 30,
                                                2015           2014     2015          2014
                                                  $M             $M       $M            $M
    CASH FLOWS FROM OPERATING ACTIVITIES:

    Net income                                 159.6          523.1    570.0         753.5
    Adjustments to reconcile net income to
    net cash provided by operating
    activities:
                   Depreciation and
                   amortization                171.2          108.3    291.8         204.8
                   Share based compensation     29.0           29.5     44.3          55.7
                   Change in fair value of
                   contingent consideration  (258.1)           80.6  (255.7)          21.4
                   Impairment of intangible
                   assets                      523.3           22.0    523.3         188.0
                   Write down of assets            -            0.9        -          13.0
                   Gain on sale of product
                   rights                      (7.1)          (3.8)   (12.3)        (40.2)
                   Unwind of inventory fair
                   value step-up                 5.1           33.8     16.3          72.5
                   Other, net                   10.0           16.2     11.1          14.1
    Movement in deferred taxes                (96.0)            6.8   (79.4)          25.3
    Equity in (earnings)/losses of equity
    method investees                           (0.1)          (3.0)      0.9         (2.4)
    Changes in operating assets and
    liabilities:
                   Decrease/(increase) in
                   accounts receivable           0.2           40.0   (84.9)        (37.3)
                   Increase in sales
                   deduction accrual            61.9           35.2     37.3         106.0
                   (Increase)/decrease in
                   inventory                  (15.4)            6.9   (37.4)        (11.7)
                   (Increase)/decrease in
                   prepayments and other
                   assets                     (14.0)         (62.9)     28.4       (137.5)
                   (Decrease)/increase in
                   accounts payable and
                   other liabilities         (117.3)            0.4   (39.8)       (145.1)
    Net cash provided by operating
    activities(A)                              452.3          834.0  1,013.9       1,080.1
   
    CASH FLOWS FROM INVESTING ACTIVITIES:

    Movements in restricted cash                 (5.0)     (1.8)      (19.5)      (11.9)
    Purchases of subsidiary undertakings and
    businesses, net of cash acquired            (49.5)   (253.9)   (5,249.2)   (4,018.3)
    Purchases of non-current investments         (2.4)     (2.8)       (4.9)       (3.1)
    Purchases of PP&E                           (20.5)     (3.8)      (39.8)      (19.1)
    Proceeds from short-term investments          12.5       9.5        67.0        56.3
    Proceeds from disposal of non-current
    investments                                    4.4         -         4.4         8.0
    Proceeds received on sale of product
    rights                                         4.9       4.8         8.8        52.8
    Other, net                                   (1.3)       0.1       (0.9)       (2.8)
    Net cash used in investing activities(B)    (56.9)   (247.9)   (5,234.1)   (3,938.1)

Unaudited US GAAP results for the three months and six months to June 30, 2015

Consolidated Statements of Cash Flows (continued) 

   
                                          3 months to June 30,       6 months to June 30,
                                        2015              2014      2015             2014
                                          $M                $M        $M               $M

    CASH FLOWS FROM FINANCING
    ACTIVITIES:

    Proceeds from revolving line of
    credit, long term and short
    term borrowings                    695.6             140.8   2,925.6          2,310.8
    Repayment of revolving line of
    credit and short term                                      (1,530.9)        (1,251.6)
    borrowings                       (995.7)           (601.4)                       
    Repayment of debt acquired
    through business combinations          -            (17.6)         -          (551.5)
    Proceeds from ViroPharma call
    options                                -                 -         -            346.7
    Payment of dividend              (110.2)            (99.6)   (110.2)           (99.6)
    Excess tax benefit associated
    with exercise of stock options       7.1               8.6      27.0             29.1
    Contingent consideration
    payments                           (2.1)             (2.5)     (4.5)           (10.3)
    Other, net                         (1.3)             (0.5)     (4.5)            (0.3)
    Net cash (used in)/provided by
    financing activities(C)          (406.6)           (572.2)   1,302.5            773.3
    Effect of foreign exchange rate
    changes on cash and cash
    equivalents (D)                      0.9               0.6     (0.7)            (1.1)
    Net (decrease)/increase in cash
    and cash equivalents(A) +(B)                                        
    +(C) +(D)                         (10.3)              14.5  (2,918.4)        (2,085.8)
    Cash and cash equivalents at
    beginning of period                 74.3             139.1   2,982.4          2,239.4
    Cash and cash equivalents at
    end of period                       64.0             153.6      64.0            153.6

Unaudited US GAAP results for the three months and six months to June 30, 2015 

Selected Notes to the Financial Statements 

(1)  Earnings Per Share ("EPS") 

   
                                     3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
                                     $M                 $M           $M                 $M

    Income from continuing
    operations                    164.1              528.3        577.0              781.4
    Loss from discontinued
    operations                    (4.5)              (5.2)        (7.0)             (27.9)

    Numerator for EPS             159.6              523.1        570.0              753.5

    Weighted average number
    of shares:
                               Millions           Millions     Millions           Millions
    Basic(1)                      590.5              586.4        589.8              585.3
    Effect of dilutive
    shares:
    Share based awards to
    employees(2)                    2.7                3.9          3.2                5.0

    Diluted                       593.2              590.3        593.0              590.3
  1. Excludes shares purchased by the EBT and under the share buy-back program and presented by Shire as treasury stock.
  2. Calculated using the treasury stock method.

The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:

   
                                     3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
                               Millions           Millions     Millions           Millions
    Share based awards to
    employees(1)                    1.0                0.3          3.2                1.2
  1. Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire's average share price during the calculation period or (b) the required performance conditions were not satisfied as at the balance sheet date.

Unaudited US GAAP results for the three months to June 30, 2015 

Selected Notes to the Financial Statements 

(2)  Analysis of revenues 

   
    3 months to June 30,       2015       2014       2015         2015
                                                        %   % of total
                                 $M         $M     change      revenue
    Net product sales:
    VYVANSE                   424.8      359.5        18%          27%
    LIALDA/MEZAVANT           157.9      143.6        10%          10%
    ELAPRASE                  146.5      152.1        -4%           9%
    CINRYZE                   138.8      129.9         7%           9%
    REPLAGAL                  116.9      130.5       -10%           8%
    FIRAZYR                   104.1       89.0        17%           7%
    ADDERALL XR                86.0       99.8       -14%           6%
    VPRIV                      84.7       89.7        -6%           5%
    PENTASA                    66.3       63.2         5%           4%
    FOSRENOL                   45.1       46.7        -3%           3%
    GATTEX/REVESTIVE           37.3          -        n/a           2%
    XAGRID                     22.8       27.9       -18%           1%
    INTUNIV                     9.5      100.0       -91%           1%
    NATPARA                     5.9          -        n/a          <1%
    Other product sales        29.6       37.7       -21%           2%
    Total product sales     1,476.2    1,469.6         0%          95%
    Royalties:
    SENSIPAR                   34.8          -        n/a           2%
    FOSRENOL                   10.8        9.4        15%          <1%
    3TC and ZEFFIX             10.5        8.3        27%          <1%
    ADDERALL XR                 6.6        4.5        45%          <1%
    INTUNIV                     6.1          -        n/a          <1%
    Other                      10.3        7.0        47%          <1%
    Total royalties            79.1       29.2       171%           5%
    Other revenues              2.3        3.3       -30%          <1%
    Total revenues          1,557.6    1,502.1         4%         100%

Unaudited US GAAP results for the six months to June 30, 2015 

Selected Notes to the Financial Statements 

(2)  Analysis of revenues 

   
    6 months to June 30,        2015        2014       2015         2015
                                                          %   % of total
                                  $M          $M     change      revenue
    Net product sales:
    VYVANSE                    841.6       710.7        18%          28%
    LIALDA/MEZAVANT            306.4       272.5        12%          10%
    ELAPRASE                   271.5       280.7        -3%           9%
    CINRYZE                    286.9       215.5        33%           9%
    REPLAGAL                   214.4       244.8       -12%           7%
    FIRAZYR                    196.6       163.9        20%           6%
    ADDERALL XR                181.7       184.9        -2%           6%
    VPRIV                      171.1       176.6        -3%           6%
    PENTASA                    145.0       135.5         7%           5%
    FOSRENOL                    89.2        88.1         1%           3%
    GATTEX/REVESTIVE            52.2           -        n/a           2%
    XAGRID                      48.1        55.0       -13%           2%
    INTUNIV                     26.9       182.3       -85%           1%
    NATPARA                      5.9           -        n/a          <1%
    Other product sales         61.9        67.2        -8%           2%
    Total product sales      2,899.4     2,777.7         4%          95%
    Royalties:
    SENSIPAR                    45.2           -        n/a           1%
    INTUNIV                     27.8           -        n/a           1%
    FOSRENOL                    19.2        22.2       -14%           1%
    3TC and ZEFFIX              18.0        15.8        14%           1%
    ADDERALL XR                 15.1        13.5        12%          <1%
    Other                       16.6        10.0        66%          <1%
    Total royalties            141.9        61.5       131%           5%
    Other revenues               4.7         9.7       -52%          <1%
    Total revenues           3,046.0     2,848.9         7%         100%

Unaudited results for the three months to June 30, 2015 

Non GAAP reconciliation 

   
    3 months to June                                                                   Non
    30, 2015           US GAAP                     Adjustments                        GAAP

                                    (a)      (b)     (c)      (d)      (e)     (f)
                            $M       $M       $M      $M       $M       $M      $M      $M
                                                                                   
    Total revenues     1,557.6        -        -       -        -        -       - 1,557.6

    Costs and
    expenses:
    Cost of product
    sales                228.0        -    (5.1)       -        -    (2.8)  (13.1)   207.0
    R&D                  775.9  (523.3)        -       -        -    (5.7)   (8.9)   238.0
    SG&A                 627.3  (131.3)        -       -    (1.9)   (17.5)  (17.9)   458.7
    Gain on sale of
    product rights       (7.1)        -        -     7.1        -        -       -       -
    Reorganization
    costs                 13.3        -        -  (13.3)        -        -       -       -
    Integration and
    acquisition costs  (212.4)        -    212.4       -        -        -       -       -
    Depreciation             -        -        -       -        -        -    39.9    39.9
    Total operating
    expenses           1,425.0  (654.6)    207.3   (6.2)    (1.9)   (26.0)       -   943.6

    Operating income     132.6    654.6  (207.3)     6.2      1.9     26.0       -   614.0

    Interest income        0.6        -        -       -        -        -       -     0.6
    Interest expense    (11.3)        -        -       -        -        -       -  (11.3)
    Other income, net    (2.0)        -        -   (3.7)        -        -       -   (5.7)
    Total other
    expense, net        (12.7)        -        -   (3.7)        -        -       -  (16.4)
    Income before
    income taxes and
    equity in earnings
    of equity method
    investees            119.9    654.6  (207.3)     2.5      1.9     26.0       -   597.6
    Income taxes          44.1  (102.5)    (6.5)   (2.7)    (0.6)    (9.2)       -  (77.4)
    Equity in earnings
    of equity method
    investees, net of
    tax                    0.1        -        -       -        -        -       -     0.1
    Income from
    continuing
    operations           164.1    552.1  (213.8)   (0.2)      1.3     16.8       -   520.3
    Loss from
    discontinued
    operations, net of
    tax                  (4.5)        -        -     4.5        -        -       -       -
    Net income           159.6    552.1  (213.8)     4.3      1.3     16.8       -   520.3
    Weighted average
    number of shares
    (millions) -
    diluted              593.2        -        -       -        -        -       -   593.2
    Diluted earnings
    per ADS              80.7c   279.3c (108.0c)    2.1c     0.6c     8.4c       -  263.1c

The following items are included in Adjustments:

a) Amortization and asset impairments: Impairment of SHP625 IPR&D intangible asset ($346.6 million), impairment of SHP608 IPR&D intangible asset ($176.7 million), amortization of intangible assets relating to intellectual property rights acquired ($131.3 million), and tax effect of adjustments;

b) Acquisition and integration activities: Unwind of NPS inventory fair value adjustments ($5.1 million), costs primarily associated with the acquisition and integration of NPS ($49.1 million), net credit associated with the integration of ViroPharma ($3.4 million) due to adjustments to estimates relating to an onerous lease provision, net credit related to the change in fair value of contingent consideration liabilities ($258.1 million), and tax effect of adjustments;

c) Divestments, reorganizations and discontinued operations: Gain on re-measurement of DAYTRANA contingent consideration to fair value ($6.0 million), gain on disposal of non-core product rights ($1.1 million), costs relating to the One Shire reorganization, including costs relating to the relocation of staff from Chesterbrook to Lexington ($13.3 million), gain on sale of long-term investment ($3.7 million), tax effect of adjustments, and loss from discontinued operations, net of tax ($4.5 million);

d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs ($1.9 million), and tax effect of adjustments;

e) Other: Costs associated with AbbVie's terminated offer for Shire ($26.0 million), and tax effect of adjustments; and

f) Depreciation reclassification: Depreciation of $39.9 million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.

Unaudited results for the three months to June 30, 2014 

Non GAAP reconciliation 

   
    3 months to June       US                                                          Non
    30, 2014             GAAP                      Adjustments                        GAAP

                                    (a)     (b)      (c)      (d)      (e)     (f)
                           $M        $M      $M       $M       $M       $M      $M      $M
                                                                             
    Total revenues    1,502.1         -       -        -        -        -       - 1,502.1

    Costs and
    expenses:
    Cost of product
    sales               277.0         -  (33.7)        -        -        -  (17.8)   225.5
    R&D                 236.9    (22.0)       -        -        -        -   (5.8)   209.1
    SG&A                496.2    (61.2)       -        -    (2.2)   (19.1)  (21.1)   392.6
    Gain on sale of
    product rights      (3.8)         -       -      3.8        -        -       -       -
    Reorganization
    costs                45.8         -       -   (45.8)        -        -       -       -
    Integration and
    acquisition costs   112.1         - (112.1)        -        -        -       -       -
    Depreciation            -         -       -        -        -        -    44.7    44.7
    Total operating   
    expenses          1,164.2    (83.2) (145.8)   (42.0)    (2.2)   (19.1)       -   871.9

    Operating income    337.9      83.2   145.8     42.0      2.2     19.1       -   630.2

    Interest income      18.7         -       -        -        -   (18.6)       -     0.1
    Interest expense   (11.1)         -       -        -        -        -       -  (11.1)
    Other
    income/(expense),
    net                   3.3         -       -        -        -        -       -     3.3
    Total other
    income/(expense),
    net                  10.9         -       -        -        -   (18.6)       -   (7.7)
    Income before
    income taxes and
    equity in earnings
    of equity method
    investees           348.8      83.2   145.8     42.0      2.2      0.5       -   622.5
    Income taxes        176.5    (31.5)  (15.3)   (12.7)    (0.8)  (216.0)       -  (99.8)
    Equity in earnings
    of equity method
    investees, net of
    tax                   3.0         -       -        -        -        -       -     3.0
    Income from
    continuing
    operations          528.3      51.7   130.5     29.3      1.4  (215.5)       -   525.7
    Loss from
    discontinued
    operations, net of
    tax                 (5.2)         -       -      5.2        -        -       -       -
    Net income          523.1      51.7   130.5     34.5      1.4  (215.5)       -   525.7
    Weighted average
    number of shares
    (millions) -
    diluted             590.3         -       -        -        -        -       -   590.3
    Diluted earnings
    per ADS            265.8c     26.5c   66.4c    17.5c     0.6c (109.5c)       -  267.3c

The following items are included in Adjustments:

a) Amortization and asset impairments: Impairment of IPR&D intangible asset ($22.0 million), amortization of intangible assets relating to intellectual property rights acquired ($61.2 million), and tax effect of adjustments;

b) Acquisition and integration activities: Unwind of ViroPharma inventory fair value adjustments ($33.7 million), costs primarily associated with the acquisition and integration of ViroPharma ($31.5 million), net charge related to the change in fair value of contingent consideration liabilities ($80.6 million), and tax effect of adjustments;

c) Divestments, reorganizations and discontinued operations: Gain on re-measurement of DAYTRANA contingent consideration to fair value ($3.8 million), costs relating to the One Shire reorganization ($45.8 million), tax effect of adjustments, and loss from discontinued operations, net of tax ($5.2 million);

d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs ($2.2 million), and tax effect of adjustments;

e) Other: Net income tax credit related to the settlement of certain tax positions with the Canadian revenue authorities ($216.0 million), related interest income received in respect of cash deposited with the Canadian revenue authorities ($18.6 million), costs associated with AbbVie's terminated offer for Shire ($19.1 million), and tax effect adjustments; and

f) Depreciation reclassification: Depreciation of $44.7 million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.

Unaudited results for the six months to June 30, 2015 

Non GAAP reconciliation 

   
    6 months to June                                                                   Non
    30, 2015           US GAAP                     Adjustments                        GAAP

                                    (a)     (b)      (c)     (d)      (e)     (f)
                            $M       $M      $M       $M      $M       $M      $M       $M

    Total revenues     3,046.0        -       -        -       -        -       -  3,046.0

    Costs and
    expenses:
    Cost of product
    sales                455.8        -  (16.3)        -       -    (5.5)  (24.8)    409.2
    R&D                  969.6  (523.3)       -        -       -   (11.5)  (11.7)    423.1
    SG&A               1,133.9  (219.6)       -        -   (2.7)   (31.0)  (35.7)    844.9
    Gain on sale of
    product rights      (12.3)        -       -     12.3       -        -       -        -
    Reorganization
    costs                 28.5        -       -   (28.5)       -        -       -        -
    Integration and
    acquisition costs  (136.7)        -   136.7        -       -        -       -        -
    Depreciation             -        -       -        -       -        -    72.2     72.2
    Total operating
    expenses           2,438.8  (742.9)   120.4   (16.2)   (2.7)   (48.0)       -  1,749.4

    Operating income     607.2    742.9 (120.4)     16.2     2.7     48.0       -  1,296.6

    Interest income        2.6        -       -        -       -    (1.1)       -      1.5
    Interest expense    (20.9)        -       -        -       -        -       -   (20.9)
    Other
    income/(expense),
    net                    2.3        -       -    (3.7)       -        -       -    (1.4)
    Total other
    expense, net        (16.0)        -       -    (3.7)       -    (1.1)       -   (20.8)
    Income before
    income taxes and
    equity in losses
    of equity method
    investees            591.2    742.9 (120.4)     12.5     2.7     46.9       -  1,275.8
    Income taxes        (13.3)  (135.6)  (20.1)    (7.1)   (1.0)   (17.0)       -  (194.1)
    Equity in losses
    of equity method
    investees, net of
    tax                  (0.9)        -       -        -       -        -       -    (0.9)
    Income from
    continuing
    operations           577.0    607.3 (140.5)      5.4     1.7     29.9       -  1,080.8
    Loss from
    discontinued
    operations, net of
    tax                  (7.0)        -       -      7.0       -        -       -        -
    Net income           570.0    607.3 (140.5)     12.4     1.7     29.9       -  1,080.8
    Weighted average
    number of shares
    (millions) -
    diluted              593.0        -       -        -       -        -       -    593.0
    Diluted earnings
    per ADS             288.3c   307.3c (71.0c)     6.4c    0.9c    15.0c       -   546.9c

The following items are included in Adjustments:

a) Amortization and asset impairments: Impairment of SHP625 IPR&D intangible asset ($346.6 million), impairment of SHP608 IPR&D intangible asset ($176.7 million), amortization of intangible assets relating to intellectual property rights acquired ($219.6 million), and tax effect of adjustments;

b) Acquisitions and integration activities: Unwind of NPS inventory fair value adjustments ($15.0 million), unwind of ViroPharma inventory fair value adjustments ($1.3 million), costs associated with acquisition and integration activities, principally NPS ($119.0 million), net credit related to the change in fair values of contingent consideration liabilities ($255.7 million), and tax effect of adjustments;

c) Divestments, reorganizations and discontinued operations: Net gain on divestment of non-core product rights and on re-measurement of DAYTRANA contingent consideration to fair value ($11.2 million), gain on disposal of non-core product rights ($1.1 million), costs relating to the One Shire reorganization, including costs relating to the relocation of staff from Chesterbrook to Lexington ($28.5 million), gain on sale of long term investments ($3.7 million), tax effect of adjustments and loss from discontinued operations, net of tax ($7.0 million);

d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs ($2.7 million), and tax effect of adjustments;

e) Other: Costs associated with AbbVie's terminated offer for Shire ($48.0 million), interest income received in respect of cash deposited with the Canadian revenue authorities ($1.1 million); and

f) Depreciation reclassification: Depreciation of $72.2 million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.

Unaudited results for the six months to June 30, 2014 

Non GAAP reconciliation 

   
    6 months to June       US                                                          Non
    30, 2014             GAAP                     Adjustments                         GAAP

                                   (a)      (b)      (c)     (d)      (e)     (f)
                           $M       $M       $M       $M      $M       $M      $M       $M
                      
    Total revenues    2,848.9        -        -        -       -        -       -  2,848.9

    Costs and
    expenses:
    Cost of product
    sales               506.5        -   (72.5)        -       -        -  (28.0)    406.0
    R&D                 597.4  (188.0)        -        -       -        -  (11.6)    397.8
    SG&A                926.5  (119.0)        -        -   (3.9)   (19.1)  (41.9)    742.6
    Gain on sale of
    product rights     (40.2)        -        -     40.2       -        -       -        -
    Reorganization
    costs                95.2        -        -   (95.2)       -        -       -        -
    Integration and
    acquisition costs   118.7        -  (118.7)        -       -        -       -        -
    Depreciation            -        -        -        -       -        -    81.5     81.5
    Total operating   
    expenses          2,204.1  (307.0)  (191.2)   (55.0)   (3.9)   (19.1)       -  1,627.9

    Operating income    644.8    307.0    191.2     55.0     3.9     19.1       -  1,221.0

    Interest income      19.2        -        -        -       -   (18.6)       -      0.6
    Interest expense   (18.9)        -        -        -       -        -       -   (18.9)
    Other expense, net    8.0        -        -    (5.0)       -        -       -      3.0
    Total other
    expense, net          8.3        -        -    (5.0)       -   (18.6)       -   (15.3)
    Income before
    income taxes and
    equity in earnings
    of equity method
    investees           653.1    307.0    191.2     50.0     3.9      0.5       -  1,205.7
    Income taxes        125.9   (76.0)   (25.5)   (25.4)   (1.4)  (216.0)       -  (218.4)
    Equity in earnings
    of equity method
    investees, net of
    tax                   2.4        -        -        -       -        -       -      2.4
    Income from
    continuing
    operations          781.4    231.0    165.7     24.6     2.5  (215.5)       -    989.7
    Loss from
    discontinued
    operations, net of
    tax                (27.9)        -        -     27.9       -        -       -        -
    Net income          753.5    231.0    165.7     52.5     2.5  (215.5)       -    989.7
    Weighted average
    number of shares
    (millions) -
    diluted             590.3        -        -        -       -        -       -    590.3
    Diluted earnings
    per ADS            382.8c   117.4c    84.4c    26.8c    1.2c (109.5c)       -   503.1c

The following items are included in Adjustments:

a) Amortization and asset impairments: Impairment of IPR&D intangible assets ($188.0 million), amortization of intangible assets relating to intellectual property rights acquired ($119.0 million), and tax effect of adjustments;

b) Acquisitions and integration activities: Unwind of ViroPharma inventory fair value adjustments ($72.5 million), costs primarily associated with the acquisition of ViroPharma ($97.3 million), charge related to the change in fair values of contingent consideration liabilities ($21.4 million), and tax effect of adjustments;

c) Divestments, reorganizations and discontinued operations: Gain on sale of CALCICHEW product rights and on re-measurement of DAYTRANA contingent consideration to fair value ($40.2 million), costs relating to the One Shire reorganization ($95.2 million), gain on sale of long term investments ($5.0 million), tax effect of adjustments and loss from discontinued operations, net of tax ($27.9 million);

d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs ($3.9 million), and tax effect of adjustments;

e) Other: Net income tax credit related to the settlement of certain tax positions with the Canadian revenue authorities ($216.0 million), related interest income received in respect of cash deposited with the Canadian revenue authorities ($18.6 million), costs associated with AbbVie's terminated offer for Shire ($19.1 million), and tax effect of adjustment; and

f) Depreciation reclassification: Depreciation of $81.5 million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.

Unaudited results for the three months and six months to June 30, 2015 

Non GAAP reconciliation 

The following table reconciles US GAAP net income to Non GAAP EBITDA:

   
                               3 months to June 30,                 6 months to June 30,
                             2015               2014              2015               2014
                               $M                 $M                $M                 $M
      US GAAP Net Income    159.6              523.1             570.0              753.5
    (Deduct) / add back:
    Loss from
    discontinued
    operations, net of
    tax                       4.5                5.2               7.0               27.9
    Equity in
    (earnings)/losses of
    equity method
    investees, net of
    taxes                   (0.1)              (3.0)               0.9              (2.4)
    Income taxes           (44.1)            (176.5)              13.3            (125.9)
    Other expense/
    (income), net             2.0              (3.3)             (2.3)              (8.0)
    Interest expense         11.3               11.1              20.9               18.9
    Interest income         (0.6)             (18.7)             (2.6)             (19.2)

    US GAAP Operating
    income from
    continuing
    operations              132.6              337.9             607.2              644.8

    Amortization            131.3               61.2             219.6              119.0
    Depreciation             39.9               44.7              72.2               81.5
    Asset impairments       523.3               22.0             523.3              188.0
    Acquisition and
    integration
    activities            (207.3)              145.8           (120.4)              191.2
    Divestments,
    reorganizations and
    discontinued
    operations                6.2               42.0              16.2               55.0
    Legal and litigation
    costs                     1.9                2.2               2.7                3.9
    Other                    26.0               19.1              48.0               19.1

    Non GAAP EBITDA         653.9              674.9           1,368.8            1,302.5

    Depreciation           (39.9)             (44.7)            (72.2)             (81.5)

    Non GAAP Operating
    income from
    continuing
    operations              614.0              630.2           1,296.6            1,221.0

    Net income margin(1)      10%                35%               19%                26%

    Non GAAP EBITDA
    margin(2)                 39%                44%               42%                44%

    (1) Net income as a percentage of total revenues

    (2) Non GAAP EBITDA as a percentage of product sales, excluding royalties and
    other revenues

Unaudited results for the three months and six months to June 30, 2015 

Non GAAP reconciliation 

The following table reconciles US GAAP product sales to Non GAAP Gross Margin:

   
                                   3 months to June 30,            6 months to June 30,
                                  2015               2014        2015               2014
                                    $M                 $M          $M                 $M
    US GAAP Product
    Sales                      1,476.2            1,469.6     2,899.4            2,777.7
    (Deduct) / add back:
    Cost of product
    sales (US GAAP)            (228.0)            (277.0)     (455.8)            (506.5)
    Unwind of inventory
    fair value step-up             5.1               33.7        16.3               72.5
    Costs of employee
    retention awards
    following AbbVie's
    terminated offer for
    Shire                          2.8                  -         5.5                  -
    Depreciation                  13.1               17.8        24.8               28.0
    Non GAAP Gross
    Margin                     1,269.2            1,244.1     2,490.2            2,371.7

    Non GAAP Gross
    Margin % (1)                 86.0%              84.7%       85.9%              85.4%

    (1) Gross Product Margin as a percentage of product sales

The following table reconciles US GAAP net cash provided by operating activities to Non GAAP cash generation:

   
                                 3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
                                     $M                 $M           $M                 $M
        Net cash provided by
        operating activities      452.3              834.0      1,013.9            1,080.1
            Tax and interest
               payments, net       53.0               72.6          7.2              157.8
            Receipt from the
            Canadian revenue
                 authorities          -            (248.0)            -            (248.0)
    Non GAAP cash generation      505.3              658.6      1,021.1              989.9

The following table reconciles US GAAP net cash provided by operating activities to Non GAAP free cash flow:

   
                                     3 months to June 30,            6 months to June 30,
                                   2015               2014         2015               2014
                                     $M                 $M           $M                 $M
        Net cash provided by
        operating activities      452.3              834.0      1,013.9            1,080.1
         Capital expenditure     (20.5)              (3.8)       (39.8)             (19.1)
     Non GAAP free cash flow      431.8              830.2        974.1            1,061.0

Non GAAP net (debt)/cash comprises:

   
                                              June 30,   December 31,
                                                 2015           2014
                                                   $M             $M

    Cash and cash equivalents                    64.0        2,982.4

    Long term borrowings                       (73.9)              -
    Short term borrowings                   (2,229.9)        (850.0)
    Other debt                                 (13.6)         (13.7)
    Non GAAP net (debt)/cash                (2,253.4)        2,118.7

NOTES TO EDITORS 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

http://www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 

Statements included herein that are not historical facts, including without limitation statements concerning our 10x20 ambitions and targets, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's products may not be a commercial success;
  • product sales from ADDERALL XR and INTUNIV are subject to generic competition;
  • the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for Shire's products may affect future revenues, financial condition and results of operations;
  • Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire's products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
  • the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  • the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire's revenues, financial condition or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • Shire faces intense competition for highly qualified personnel from other companies and organizations. Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect Shire's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
  • failure to achieve Shire's strategic objectives with respect to the acquisition of NPS Pharmaceuticals Inc. may adversely affect Shire's financial condition and results of operations; and

other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including those risks outlined in "Item 1A: Risk Factors" in Shire's Annual Report on Form 10-K for the year ended December 31, 2014.

NON GAAP MEASURES 

This press release contains financial measures not prepared in accordance with US GAAP. These measures are referred to as "Non GAAP" measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effective tax rate on Non GAAP income before income taxes and earnings/(losses) of equity method investees ("effective tax rate on Non GAAP income"); Non GAAP cost of product sales; Non GAAP gross margin; Non GAAP R&D; Non GAAP SG&A; Non GAAP other income/(expense); Non GAAP interest income; Non GAAP cash generation; Non GAAP free cash flow, Non GAAP net cash/(debt), Non GAAP EBITDA and Non GAAP EBITDA margin (excluding royalties and other revenues)(1). These Non GAAP measures exclude the effect of certain cash and non-cash items that Shire's management believes are not related to the core performance of Shire's business.

These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of Shire's performance to historical results and to competitors' results. Shire's Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire's directors.

The Non GAAP measures are presented in this press release as Shire's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, Shire's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.

Where applicable the following items, including their tax effect, have been excluded when calculating Non GAAP earnings for both 2015 and 2014, and from our Outlook:

Amortization and asset impairments: 

  • Intangible asset amortization and impairment charges; and
  • Other than temporary impairment of investments.

Acquisitions and integration activities: 

  • Up-front payments and milestones in respect of in-licensed and acquired products;
  • Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquired inventory;
  • Costs associated with the integration of companies; and
  • Noncontrolling interests in consolidated variable interest entities.

Divestments, reorganizations and discontinued operations: 

  • Gains and losses on the sale of non-core assets;
  • Costs associated with restructuring and reorganization activities;
  • Termination costs; and
  • Income/(losses) from discontinued operations.

Legal and litigation costs: 

  • Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal legal team costs).

Other: 

  • Net income tax credit (being income tax, interest and estimated penalties) related to the settlement of certain tax positions with the Canadian revenue authorities;
  • Costs associated with AbbVie's terminated offer for Shire, including costs of employee retention awards; and
  • Break fee received in relation to AbbVie's terminated offer for Shire.

Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2015 and 2014 Non GAAP earnings.

--------------------------------------------------

1.) Non GAAP EBITDA (as calculated on page 25 of this announcement) as a percentage of product sales, excluding royalties and other revenues.

Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments.  

Free cash flow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business.  

A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented on pages 21 to 26.

Growth at CER, which is a Non GAAP measure, is computed by restating 2015 results using average 2014 foreign exchange rates for the relevant period.

Average exchange rates used by Shire for the six months to June 30, 2015 were $1.53:£1.00 and $1.13:€1.00 (2014: $1.67:£1.00 and $1.37:€1.00). Average exchange rates used by Shire for Q2 2015 were $1.52:£1.00 and $1.10:€1.00 (2014: $1.68:£1.00 and $1.38:€1.00).

TRADE MARKS 

All trade marks designated ® and ™ used in this press release are trade marks of Shire plc or companies within the Shire group except for 3TC® and ZEFFIX® which are trade marks of GlaxoSmithKline, PENTASA® which is a trade mark of FERRING B.V. Corp, LIALDA® which is a trade mark of Nogra International Limited, MEZAVANT® which is a trade mark of Guiliani International Limited, CALCICHEW® which is a trade mark of Takeda and DAYTRANA® which is a trade mark of Noven Pharmaceutical Inc. Certain trade marks of Shire plc or companies within the Shire group are set out in Shire's most recent Annual Report on Form 10-K for the year ended December 31, 2014.

For further information please contact:

Investor Relations        
     - Sarah Elton-Farr, seltonfarr@shire.com , +44-1256-894-157
             
Media        
     - Michele Galen, mgalen@shire.com , +1-781-482-1867
     - Brooke Clarke, brclarke@shire.com , +44-1256-894-829

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.